Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency sent Validus Pharmaceuticals a letter objecting to web pages that minimize the risk of suicidality with use of the bipolar disorder drug and suggest it does not worsen depression or induce weight gain.


Related Content

MS Product Ads Kept On Short (Study) Leash As Avonex Draws FDA Letter
Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns
CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs
Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts